Xiaoyan Ding

Xiaoyan Ding

Auto-generated profile, based on publicly available information

Xiaoyan Ding

Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 July 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
XLXiaomi Li
Xiaomi Li
WLWen-Dong Li
Wen-Dong Li
XDXiaoyan Ding
Xiaoyan Ding
YZYongchao Zhang
Yongchao Zhang
WLWei Li
Wei Li
Objective: To describe and analyze the predictive models of the prognosis of patients with hepatocellular carcinoma (HCC) undergoing systemic treatment. Design: Systematic review. Data sources: PubMed and Embase until December 2020 and manually searched references from eligible articles. Eligibility criteria for study selection: The development, validation, or updating of prognostic models of patients with HCC after systemic treatment. Results: The systematic search yielded 42 eligible articles: 28 articles described the development of 28 prognostic models of patients with HCC treated with systemic therapy, and 14 articles described the external validation of 32 existing prognostic models of patients with HCC undergoing systemic treatment. Among the 28 prognostic models, six were developed based on genes, of which five were expressed in full equations; the other 22 prognostic models were developed based on common clinical factors. Of the 28 prognostic models, 11 were validated both internally and externally, nine were validated only internally, two were validated only externally, and the remaining six models did not undergo any type of validation. Among the 28 prognostic models, the most common systemic treatment was sorafenib (n = 19); the most prevalent endpoint was overall survival (n = 28); and the most commonly used predictors were alpha-fetoprotein (n = 15), bilirubin (n = 8), albumin (n = 8), Child–Pugh score (n = 8), extrahepatic metastasis (n = 7), and tumor size (n = 7). Further, among 32 externally validated prognostic models, 12 were externally validated > 3 times. Conclusions: This study describes and analyzes the prognostic models developed and validated for patients with HCC who have undergone systemic treatment. The results show that there are some methodological flaws in the model development process, and that external validation is rarely performed. Future research should focus on validating and updating existing models, and evaluating the effects of these models in clinical practice. Systematic review registration: PROSPERO CRD42020200187.

1 January 2020
Verified
Journal Article
Closed access
WSWei Sun
Wei Sun
WLWendong Li
Wendong Li
JCJinglong Chen
Jinglong Chen
YTYing Teng
Ying Teng
XDXiaoyan Ding
Xiaoyan Ding